3,632 Shares of Stryker Corporation $SYK Bought by Value Partners Investments Inc.

Value Partners Investments Inc. bought a new position in shares of Stryker Corporation (NYSE:SYK) in the third quarter, HoldingsChannel reports. The firm bought 3,632 shares of the medical technology company’s stock, valued at approximately $1,002,000.

Several other institutional investors and hedge funds also recently modified their holdings of SYK. Mitchell Mcleod Pugh & Williams Inc. increased its stake in shares of Stryker by 1.2% during the 1st quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company’s stock worth $880,000 after purchasing an additional 31 shares in the last quarter. Community Bank & Trust Waco Texas lifted its stake in Stryker by 2.3% in the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock valued at $439,000 after buying an additional 31 shares in the last quarter. Cornerstone Financial Management LLC lifted its stake in Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after buying an additional 31 shares in the last quarter. NWF Advisory Services Inc. grew its holdings in Stryker by 2.3% during the 2nd quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after buying an additional 33 shares during the last quarter. Finally, Harold Davidson & Associates Inc. grew its holdings in Stryker by 0.4% during the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock valued at $2,848,000 after buying an additional 34 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In related news, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 351,267 shares of company stock worth $118,197,701 over the last quarter. 4.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Citizens Jmp reduced their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Argus set a $370.00 price objective on Stryker in a research note on Thursday, July 9th. TD Cowen decreased their price objective on Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research note on Tuesday, September 22nd. Finally, Piper Sandler dropped their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $369.00.

Stryker Trading Up 1.4%

Shares of SYK traded up $4.25 on Monday, hitting $298.91. 3,064,306 shares of the stock traded hands, compared to its average volume of 2,453,146. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $114.65 billion, a P/E ratio of 30.98, a P/E/G ratio of 1.87 and a beta of 0.78. The stock’s 50 day moving average is $298.39 and its two-hundred day moving average is $312.55. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $392.55.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is 36.48%.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.